China publishes new patent law amendment

Home/Policies & Legislation | Posted 24/07/2020 post-comment0 Post your comment

On 3 July 2020, China’s Standing Committee of the National People's Congress published a second draft amendment to its Patent Law. This introduces patent linkage, patent term extension and patent term adjustment. It expands on several provisions to improve protection for new drugs laid out in the first draft amendment published in 2019.

10 AA008993

Article 42 of this second draft amendment patent term extension/restoration (PTE) states that the China National IP Administration can add up to five years to the invention patent of a new drug that has obtained marketing authorization approval. This is to compensate commercialization delays caused by regulatory review and approval. In addition, the total patent term cannot exceed 14 years following new drug launch.

Article 42 also incorporates the concept of patent term adjustment (PTA). Here, the patent term of invention patent is adjusted to compensate for unreasonable delays due to patent examination by the patent administrative authority. However, the PTA calculation method for PTA needs to be further clarified.

In addition, Article 75 introduces patent linkage and addresses China’s commitment in the 2020 US-China Economic Trade Agreement. This includes details of protocols for legal challenges by the originator/patent holder and for regulatory review and administrative appeal. In addition, it mentions the establishment of coordination between drug and patent administrative authorities.

It has been noted that there are parallels between China’s second draft amendment and the US patent linkage regime. However, the second draft amendment presents some uncertainties and differences to the US patent linkage system.

Overall, this second draft amendment makes it clear that China hopes to balance pharmaceutical innovation and affordability.

Related articles
Chinese company makes copy of patented coronavirus treatment remdesivir

Further collaborations formed to penetrate China’s generics market

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
More drugmakers sue over IRA yet one withdraws
Law V13C29
Home/Policies & Legislation Posted 10/10/2023
First drugs for Medicare price negotiation selected
34 AA010660
Home/Policies & Legislation Posted 22/09/2023
Updated Biosimilar Red Tape Elimination Act introduced by Senator Lee
Interchangeability V18K30
Home/Policies & Legislation Posted 25/08/2023
Inflation Reduction Act explained
Regulation V13H16
Home/Policies & Legislation Posted 24/07/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010